ROS1 and adenocarcinoma: The patient who responded in the single-arm study (Table 2 patient S5) was heterozygous for HLA-A*02:01 and had a poorly differentiated adenocarcinoma without EGFR, ALK, or ROS1 pretreatment alterations, or any other targetable oncogenic mutations.